Statin-Associated Muscle Symptoms: Identification and Recommendations for Management.

IF 5.7 2区医学 Q1 PERIPHERAL VASCULAR DISEASE

Current Atherosclerosis Reports Pub Date : 2024-11-18 DOI:10.1007/s11883-024-01246-y

Kevin C Maki, Carol F Kirkpatrick, Mary Katherine Cheeley, Terry A Jacobson

{"title":"Statin-Associated Muscle Symptoms: Identification and Recommendations for Management.","authors":"Kevin C Maki, Carol F Kirkpatrick, Mary Katherine Cheeley, Terry A Jacobson","doi":"10.1007/s11883-024-01246-y","DOIUrl":null,"url":null,"abstract":"Purpose of review: Statins are first-line pharmacotherapy for the treatment of elevated low-density lipoprotein cholesterol and are generally well-tolerated. However, some patients may experience statin-associated muscle symptoms (SAMS). This paper reviews recommendations for identification and management of patients with SAMS.Recent findings: The National Lipid Association and other professional societies have issued guidance to assist clinicians in identifying and managing patients with partial or complete statin intolerance. The most common reason for intolerance is SAMS. This review discusses strategies to achieve therapeutic objectives for atherogenic lipoprotein management in patients with SAMS. Many patients who experience SAMS can tolerate some degree of statin therapy and non-statin medications are available as adjunctive or alternative treatments. With a thorough clinician-patient discussion and shared decision-making, a treatment plan can be identified to achieve therapeutic objectives and reduce the risk of atherosclerotic cardiovascular disease.","PeriodicalId":10875,"journal":{"name":"Current Atherosclerosis Reports","volume":"27 1","pages":"5"},"PeriodicalIF":5.7000,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Atherosclerosis Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11883-024-01246-y","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: Statins are first-line pharmacotherapy for the treatment of elevated low-density lipoprotein cholesterol and are generally well-tolerated. However, some patients may experience statin-associated muscle symptoms (SAMS). This paper reviews recommendations for identification and management of patients with SAMS.

Recent findings: The National Lipid Association and other professional societies have issued guidance to assist clinicians in identifying and managing patients with partial or complete statin intolerance. The most common reason for intolerance is SAMS. This review discusses strategies to achieve therapeutic objectives for atherogenic lipoprotein management in patients with SAMS. Many patients who experience SAMS can tolerate some degree of statin therapy and non-statin medications are available as adjunctive or alternative treatments. With a thorough clinician-patient discussion and shared decision-making, a treatment plan can be identified to achieve therapeutic objectives and reduce the risk of atherosclerotic cardiovascular disease.

查看原文本刊更多论文

他汀类药物相关肌肉症状：识别与管理建议》。

审查目的：他汀类药物是治疗低密度脂蛋白胆固醇升高的一线药物疗法，一般耐受性良好。然而，一些患者可能会出现他汀类药物相关肌肉症状（SAMS）。本文回顾了有关识别和处理 SAMS 患者的建议：美国国家血脂协会和其他专业协会已发布指南，帮助临床医生识别和管理部分或完全不耐受他汀类药物的患者。不耐受的最常见原因是 SAMS。本综述讨论了如何实现 SAMS 患者致动脉粥样硬化脂蛋白管理治疗目标的策略。许多出现 SAMS 的患者可以耐受一定程度的他汀类药物治疗，非他汀类药物可作为辅助或替代治疗。通过临床医生与患者的充分讨论和共同决策，可以确定治疗方案，以实现治疗目标并降低动脉粥样硬化性心血管疾病的风险。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Atherosclerosis Reports 医学-

CiteScore

9.00

自引率

3.40%

发文量

审稿时长

6-12 weeks

期刊介绍： The aim of this journal is to systematically provide expert views on current basic science and clinical advances in the field of atherosclerosis and highlight the most important developments likely to transform the field of cardiovascular prevention, diagnosis, and treatment. We accomplish this aim by appointing major authorities to serve as Section Editors who select leading experts from around the world to provide definitive reviews on key topics and papers published in the past year. We also provide supplementary reviews and commentaries from well-known figures in the field. An Editorial Board of internationally diverse members suggests topics of special interest to their country/region and ensures that topics are current and include emerging research.